As autism rises…you can look to these invasive vaccines to be the cause.
Patent awarded for HPV work to University of Rochester researchers
by Sean Lahman Staff writer
Last month, three researchers at the University of Rochester were granted a patent for their pioneering work that led to the development of vaccines for human papillomavirus. The three UR virologists — Richard Reichman, William Bonnez and Robert Rose — have spent more than 20 years studying the virus, commonly known as HPV, which has been linked to cervical cancer.
They didn’t set out to develop a cancer vaccine. In the mid-1980s, the trio was simply trying to develop a blood test to determine whether a patient was infected with HPV.
…some types cause warts and a few, in a small percentage of cases, can lead to cancer.
The link between HPV and cervical cancer was discovered in 1983 by Harald zur Hausen, a German doctor. He received the Nobel Prize in Medicine in 2008 for his discovery. But in the mid-1980s, doctors didn’t have a way to identify whether someone had been infected with HPV, and zur Hausen’s discovery added a sense of urgency.
To develop a blood test, researchers must find an antigen, a substance that triggers the immune system to create antibodies to fight intruders.
Reichman, Bonnez and Rose tried for years to develop an antigen and had mostly encountered dead ends.
But during the early 1990s, the trio discovered that they could use virus-like particles to mimic HPV 16, one of the most virulent types of HPV. The virus-like particles carry no risk of infection themselves, but they provoke the creation of antibodies to combat infection.
The Rochester team conducted the first tests, which showed that the virus-like particles were not only safe but would consistently trigger the antibodies that would prevent infection and provide immunity.
The technology was licensed to GlaxoSmithKline, which developed a vaccine under the brand name Cervarix. Another pharmaceutical company, Merck, developed its own version of the vaccine called Gardasil.
In 2006, the Advisory Committee on Immunization Practices at the Centers for Disease Control recommended that the vaccine be given to girls age 11-12, and also for teen girls and young women through age 26 who hadn’t already received the vaccine. In October, they also recommended that boys age 11-12 receive the vaccine. More than 40 million doses of HPV vaccine have already been distributed in the United States.
a12iggymom's Blog 